ClinicalTrials.gg
Not yet recruitingNCT07870096STRIVE-251Updated Oct 13, 2026

ITR-251 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ITR-251 and ITR-251 at RP2D in Solid Tumor Cancer and Castration Resistant Metastatic Prostate Cancer, sponsored by ITERIA BIOPHARMA, S.L.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by ITERIA BIOPHARMA, S.L. · Phase 1, Interventional, and Treatment

How we know

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Prostatic Neoplasms with a site in Spain — 72 open to participants now, 126 under way, 45 of them phase 3. Prostatic Neoplasms · Spain.

Planned enrollment
232nd of 257
46 · median 268
Started
2026
with 13 others
Phase 1
37 of 312
12 open now
Primary completion
2029-07
later than 101 of 125 live
Registered
312th of 312
by date

Among the 312 studies in Prostatic Neoplasms with a site in Spain, this one is the 232nd largest by planned enrollment of the 257 interventional ones that give a count, is one of 14 that started in 2026, is one of 37 in phase 1, reaches primary completion later than 101 of the 125 other live ones, and was the 312th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

72 of the 312 studies in Prostatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Prostatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway Inhibitors (ARPi) in patients with metastatic castration resistant prostate cancer (mCRPC).

The trial will enroll following a 3+3 design up to 6 patients with any type of solid tumors after progression to standard treatments at each dose level during the dose-escalation phase. Four dose levels are planned. If the first DL is deemed not safe, the next patients could be treated at a lower dose. If further reductions are required, the study will be stopped. After determining the RP2D, the trial will enroll up to 20 additional evaluable patients with mCRPC during the dose-expansion phase. The first six patients enrolled in the dose-expansion phase will be the safety lead in cohort for the combination and will be monitored for DLTs. The rest of patients will be enrolled afterwards at the RP2D if found safe or with a lower ITR-251 dose level if the combination shows unacceptable toxicity.

The study aims to determine the RP2D of ITR-251 and the safety in combination with ARPi in mCRPC. Secondary objectives includes duration of treatment, tolerability, pharmacokinetics, and preliminary signs of antitumoral activity and efficacy. Pharmacodynamics will be an exploratory objective.

03

Conditions studied

  • Solid Tumor Cancer
  • Castration Resistant Metastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be fully informed about the study and sign the form (ICF) before any study specific assessment.
  2. Patients ≥18 years old at the time of signing the informed consent.
  3. (ECOG) performance status of 0 to 1 prior to study entry.
  4. Have per v1.1 or PCWG4 criteria (for mCRPC).
  5. Adequate organ and bone marrow function as follows (subject must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory):

    1. (ANC) ≥ 1.5 x109/L;
    2. ≥ 100 x109/L;
    3. ≥ 9.0 g/dl;
    4. (PT) or international normalised ratio (INR) ≤1.5 × ;
    5. Total level ≤ 1.5 x institutional upper limit of normal (ULN), except for patients with Gilbert's disease ≤ 5.0 x ULN;
    6. (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN;
    7. Creatinine ≤ 1.5 x ULN;
    8. (CrCl) ≥ 30 mL/min;
    9. Albumin > 25 g/L.

    Criteria Specific for Dose-escalation phase:

  6. Patients with any or cytologically confirmed solid tumor at advanced or stage.

    Note: glioblastoma, cholangiocarcinoma, gastric, liver, or nasopharyngeal carcinomas are excluded given the potential negative impact of MAO-A inhibition and effect in reactive oxygen species (ROS) metabolism in these tumor types.

  7. Disease progression to standard of care therapies within one month prior to study entry.

    Note: Patients should have no available standard of care therapy likely to confer clinical benefit in the opinion of the investigator.

  8. > 6 months.

    Criteria Specific for Dose-expansion phase:

  9. Patients with histologically or cytologically confirmed mCRPC receiving ARPi treatment (including: abiraterone, apalutamide, enzalutamide or darolutamide) and experiencing PSA progression (any increase above 0.2 ng/mL in PSA level from baseline/nadir, confirmed by one additional rising PSA measurement at least 21 days apart) confirmed.

    Note: the inclusion of patients will be limited to 50% with abiraterone and 50% with androgen receptor targeted agents (ARTAs).

    Note: Patients should have castration resistant prostate cancer (CRPC) as defined by PCWG4 criteria.

    Note: patients with prior therapies for locoregional disease and/or initiating ARPis in the hormone-sensitive that progressed to CRPC setting are eligible.

    Note: Patients candidates for concurrent treatment with androgen deprivation therapy (ADT) according to the standard clinical practice are allowed.

  10. Patients with a Charlson score ≤ 3 prior to study entry.

    and other requirements:

  11. Participants who have pregnant partners must use a condom and those with partners of must use a condom and another adequate birth control measure if engaging in sexual activities during the study treatment period and for at least 4 weeks after the last dose of ITR-251. A highly effective method of birth control is defined as those which result in low failure rate (i.e., less than 1% per year) when used consistently and correctly.
  12. During the dose-escalation phase, women of childbearing potential (WOCBP) and their partners must agree to use a highly effective method of birth control during the study treatment period and for at least 4 weeks after the last dose of ITR-251.
  13. Are willing and able to comply with scheduled visits, treatment schedule, the planned trial assessments, lifestyle restrictions, and other requirements of the trial. This includes that they are able to understand and follow trial-related instructions.

Exclusion criteria

Exclusion Criteria:

  1. For Dose-escalation phase only: women pregnant or breastfeeding.
  2. For Dose-escalation phase only: Patients with glioblastoma, cholangiocarcinoma, gastric, liver, or nasopharyngeal carcinomas.
  3. For dose-expansion phase only: patients with symptomatic or radiologic PD requiring or tributary for treatment with docetaxel or other concurrent anticancer therapies other than ADT and ARPi.
  4. Patients with .
  5. Required concurrent treatment with other medicinal products or participation in other clinical trials.
  6. Previous treatment with MAO-A inhibitors.
  7. Treatment with antidepressant or psychostimulants, opioids or analgesics, antitussives and antihistaminics listed as prohibited concomitant medication within one month or 5 halflives, whichever is longer, prior to the study entry or patients with foreseen potential requirement of antidepressants during the study.
  8. Previous systemic anticancer treatments should have been discontinued 15 days prior to study entry.

    Note for dose-expansion phase: Continuous treatment with ADT and ARPi before start of study treatment is allowed.

  9. Residual toxicity from prior anticancer therapy that are v6.0 Grade ≥ 2, except for Grade ≥ 2 alopecia.

    Note: Stable chronic Grade 2 toxicities from previous treatments may be eligible per the judgement of the investigator.

  10. Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of trial treatment or are planned to undergo major surgery during the course of the trial.
  11. Known secondary active requiring treatment within the last 2 years prior to study entry.

    Note: Patients that have secondary malignancies that have undergone potentially curative therapy are eligible.

  12. (BMI) \< 15 kg/m2 or patients with symptomatic malnutrition (GLIM criteria).
  13. Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] > 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit).

    Note: patients may be rescreened after adjustment of antihypertensive medications.

  14. History of hypertensive crisis.
  15. Known prior history of mania or major psychiatric illness (schizophrenia, bipolar disorder, severe major depression requiring hospitalization, psychosis, etc.).
  16. Patients with a pre-existing diagnosis of severe insomnia (Grade 3 according to CTCAE v6.0) or primary sleep disorders (e.g., severe obstructive sleep apnea, narcolepsy) who have required adjustments to their pharmacological treatment in the 28 days prior to inclusion.
  17. Patients at high risk (i.e. categories 4, 5, or any suicide behaviors [6-9]) of suicide according to the validated Columbia Scale (C-SSRS).
  18. Patients with ongoing or active severe infections requiring treatment.
  19. Patients with symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
  20. History of stroke or significant cerebrovascular disease (ie, ) within 6 months prior to initiation of study intervention.
  21. History of cardiac disease within 6 months prior to the initiation of study intervention, including but not limited to unstable angina, acute myocardial infarction, endoscopic or open-heart cardiac surgery, or heart failure classified as Grade ≥ 2, \<45% or interval corrected by Fridericia () >470 ms (for women) and >450 ms (for men) or clinically significant arrhythmias.
  22. History of clinically significant respiratory disease within 6 months prior to the initiation of study intervention, including severe or asthma.
  23. History of noninfectious interstitial lung disease (ILD) /pneumonitis /radiation pneumonitis that required or has current ILD/pneumonitis.
  24. Clinically significant gastrointestinal disorder including bleeding, occlusion, diarrhoea >Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.
  25. Any intercurrent gastrointestinal condition that may affect the ingestion and absorption of ITR-251.
  26. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ITR-251 or other monoamine oxidase inhibitors.
  27. History or current drug abuse.
  28. Uncontrolled intercurrent illness, or condition or psychiatric illness/social situations that would limit compliance with study requirements.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Dose-Escalation

    Dose-Escalation will establish a recommended Phase 2 dose (RP2D) of ITR-251

    Drug: ITR-251

  • Experimental
    Dose-Expansion

    On completion of dose-escalation, dose-expansion will determine safety and preliminary efficacy of ITR-251 at RP2D in combination with ARPIs for mCRPC

    Drug: ITR-251 at RP2D · Drug: ARPI therapy · Drug: Androgen Deprivation Therapy (ADT)

Interventions

  • DrugITR-251

    ITR-251 is a potent and selective inhibitor of Monoamine Oxidase A (MAO-A) with reversible inhibition and limited capacity for blood brain barrier (BBB) crossing. Four dose levels will be tested. Dose could be also reduced to dose level -1.

  • DrugITR-251 at RP2D

    ITR-251 is a potent and selective inhibitor of MAO-A with reversible inhibition and limited capacity for blood brain barrier (BBB) crossing. Dose at RP2D

  • DrugARPI therapy

    ARPIs are blockers of the androgen receptor pathway, which play a pivotal role in treating prostate cancer, showing significant efficacy across different disease stages. ARPi will be given according to standard clinical practice

  • DrugAndrogen Deprivation Therapy (ADT)

    ADTs reduce availability of male hormones (androgens like testosterone) that fuel cancer growth and it is the backbone for many standard treatment combinations in prostate cancer, including in the castration resistant setting in combination with ARPis. ADT will be given according to standard clinical practice.

06

What researchers measure

Primary outcomes

  1. RP2D of ITR-251

    During dose-escalation phase, patients will be included sequentially into cohorts with escalating dose levels. RP2D is defined as the highest dose level at which \<33% of patients reported a dose limiting toxicities (DLT) (i.e. ≤ 1 DLT out of 6 patients) providing the safety profile is amenable. DLT is defined as any of the following events during the DLT reporting period: 1. Hematologic toxicities: 1. Grade (G) 3 febrile neutropenia lasting \> 7 days 2. G4 thrombocytopenia lasting \> 7 days 3. G3 thrombocytopenia with clinically significant bleeding 4. Gr ≥3 anemia requiring urgent transfusion support 2. Non-hematologic toxicities: 1. Any G ≥3 non-hematologic toxicity, excluding non relevant nausea, vomiting, or diarrhea, laboratory abnormalities or cutaneous events. 2. Hypertensive crisis 3. Severe serotonin syndrome 4. G ≥3 arrhythmia 5. QTcF prolongation \>500 ms or increase \>60 ms from baseline 3. Received \< 75% of the intended ITR-251 dose during the DLT period due to toxicity

    Time frame: DLT period is 28 days since first dose of study treatment

  2. Treatment-emergent adverse events

    incidence of treatment-emergent adverse events (TEAEs) classified by grade and seriousness

    Time frame: Throughout the study period, approximately 12 months

Secondary outcomes

  1. Duration of treatment

    Defined as the time from the first dose of ITR-251 to the permanent discontinuation of ITR-251 treatment for any reason. Patients with treatment ongoing will have their last administration date as the last date on treatment for timing calculation.

    Time frame: Throughout the study period, approximately 12 months

  2. Incidence of treatment modifications

    number of patients requiring treatment dose reduction, interruptions and permanent discontinuations for management of TEAEs

    Time frame: Throughout the study period, approximately 12 months

  3. Pharmacokinetic (PK) profile

    Cmax and Tmax of ITR-251 will be reported. The study will include analysis of patients in fasted and fed conditions

    Time frame: Within the first months of treatment with ITR-251

  4. Objective response rate (ORR)

    Proportion of patient who achieved a complete response (CR) or partial response (PR) according to prostate cancer working group (PCWG4) (in case of prostate cancer) or RECIST V1.1 (all other tumors). ORR will be assessed by investigators using computed tomography (CT) or magnetic resonance imaging (MRI) scans.

    Time frame: Throughout the study period, approximately 12 months

  5. Time to progression (TTP)

    Only for dose-escalation phase. Defined as the time elapsed from first dose of ITR-251 treatment until the date of disease progression assessed by the local investigators according to RECIST V1.1 criteria

    Time frame: Throughout the study period, approximately 12 months

  6. Radiological progression-free survival (rPFS)

    Only dose-expansion phase. Assessed by investigator according to PCWG4 Criteria and defined from the day of first dose of ITR-251 to the day the first event of radiological progression or death (due to any cause) is recorded. rPFS will be estimated by Kaplan-Meier method. Patients who are alive without evidence of radiological progression at their last imaging assessment will be censored at that date.

    Time frame: Throughout the study period, approximately 12 months

  7. Prostate specific antigen (PSA) response rates

    Only dose-expansion phase. defined as blood PSA \<0.02 ng/mL confirmed with a subsequent PSA value \<0.02 ng/mL 3 or more weeks later. Rate of absolute PSA response is defined as the number of subjects with absolute PSA response, divided by the total number of subjects evaluable for absolute PSA response (with high PSA levels at baseline).

    Time frame: Throughout the study period, approximately 12 months

  8. Time to PSA progression

    Only dose-expansion phase. Defined as the time elapsed from first dose of ITR-251 treatment until the date of any increase in PSA level from baseline/nadir, confirmed by one additional rising PSA measurement and with a minimum absolute increase of 0.2 ng/mL.

    Time frame: Throughout the study period, approximately 12 months

  9. Duration of Response (DoR)

    Only dose-expansion phase. Time from first response (CR or PR), according to ORR definition for the trial, to the date of the documented disease progression (PD) as determined using RECIST 1.1 / PCWG4 criteria (patients with mCRPC) or death due to any cause, whichever occurs first. Those patients with response and without PD or death event will be censored on the date of their last tumor assessment.

    Time frame: Throughout the study period, approximately 12 months

  10. Disease control rate (DCR)

    Only dose-expansion phase. Defined as the proportion of patients who had CR, PR, or a stable disease (SD) maintained at least for 3 months as their best response throughout the study period, defined as PCWG4 criteria.

    Time frame: Throughout the study period, approximately 12 months

  11. Time to pain progression (TTPP)

    Only dose-expansion phase. Time-to-pain progression is defined as the time (days) from the first dose of study treatment (ITR-251) date, to the date of pain progression measured according to Brief Pain Inventory (BPI). Pain progression is defined in patients in the 'pain evaluable' population as: an increase of 2 or more points in the BPI's "worst pain in 24 hours"-score from baseline observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short or long-acting opioid use for pain.

    Time frame: Throughout the study period, approximately 12 months

  12. Time to next treatment (TTNT)

    Only dose-expansion phase. This is the interval of time between first dose of study treatment and the first day of initiation of a next line of systemic antineoplastic therapy after the initial scheduled treatment.

    Time frame: Throughout the study period, approximately 12 months

  13. Overall survival (OS)

    Only dose-expansion phase. OS will be measured from the date of first dose of study treatment (ITR-251) to the date of death whatever the cause of death. OS will be estimated by Kaplan-Meier method. Patients who are alive are censored at the date of the most recent follow-up examination.

    Time frame: Throughout the study period, approximately 12 months

07

Study locations

1 site
  • Institut Català d'Oncologia (ICO)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2029, 33 months later.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 33 months is below that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartEst.
Oct 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07870096
Lead sponsor
ITERIA BIOPHARMA, S.L.
Collaborators
MFAR
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

MFAR Clinical Research
Contact
investigacio@mfar.net
0034934344412
Cristina López Sanjurjo
Contact
clopez@iteriabiopharma.com
Josep M Piulats, M.D.; Ph.D.
study chair · Institut Català d'Oncologia (ICO)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion